Pulmonary vascular abnormalities in cirrhosis.

Area of Science:

• Pulmonary vascular medicine
• Hepatology
• Cardiopulmonary interactions

Background:

• Liver disease and portal hypertension are associated with two distinct pulmonary vascular disorders: hepatopulmonary syndrome (HPS) and portopulmonary hypertension (POPH).
• HPS involves intrapulmonary vascular dilatations, while POPH is characterized by elevated pulmonary vascular resistance.
• These conditions exhibit different pulmonary microvascular remodeling patterns and pathophysiological mechanisms, though portal hypertension is implicated in their development.

Purpose of the Study:

• To differentiate the clinical presentations, underlying mechanisms, and outcomes of hepatopulmonary syndrome (HPS) and portopulmonary hypertension (POPH) in patients with liver disease.
• To explore the relationship between the severity of liver disease and the manifestation of HPS and POPH.
• To evaluate the impact of liver transplantation on HPS and POPH.

Main Methods:

• Comparative analysis of clinical features and pathophysiological characteristics of HPS and POPH.
• Review of existing literature and case reports on pulmonary vascular disorders in liver disease.
• Assessment of the correlation between hepatic impairment severity and the severity of HPS and POPH.

Main Results:

• HPS and POPH present with distinct clinical manifestations: gas exchange impairment in HPS and hemodynamic failure in POPH.
• HPS severity often correlates with liver failure severity, whereas POPH severity shows no clear relationship with hepatic impairment.
• HPS frequently resolves post-liver transplantation, while the effect of transplantation on POPH remains uncertain.

Conclusions:

• Hepatopulmonary syndrome and portopulmonary hypertension are distinct entities arising from portal hypertension, each with unique clinical profiles and treatment responses.
• Liver transplantation offers a potential resolution for HPS, but its efficacy in treating POPH requires further investigation.
• Understanding these differences is crucial for accurate diagnosis and management of pulmonary complications in liver disease patients.